Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650896 | 0.90 | VCAM1 (0.44) | VCAM1ALDH1A1HIF1ALMNAAMY1A | |
| SCHEMBL2649876 | 0.81 | VCAM1 (0.49) | VCAM1ALDH1A1HIF1ALMNAPTPRC | |
| SCHEMBL2648687 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HIF1AAMY1AGCGRMAPK14 | |
| SCHEMBL2649443 | 0.80 | VCAM1 (0.48) | VCAM1ALDH1A1HIF1ALMNAAMY1A | |
| SCHEMBL19955395 | 0.79 | CLK1 (0.47) | SLC22A12MEN1KMT2A | |
| SCHEMBL2652375 | 0.77 | GABRA1 (0.43) | VCAM1ALDH1A1HIF1ALMNAAMY1A | |
| SCHEMBL2649279 | 0.77 | VCAM1 (0.48) | VCAM1ALDH1A1HIF1ALMNAPTPRC | |
| SCHEMBL21296145 | 0.76 | SLC22A12 (0.45) | VCAM1SLC22A12 | |
| SCHEMBL2651669 | 0.76 | CYP11B1 (0.41) | SLC22A12HTTMEN1KMT2A | |
| SCHEMBL2651505 | 0.76 | CYP11B2 (0.41) | ALDH1A1GAASMN1; SMN2SLC22A12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| EP-1381606-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | VCAM1 2786/4885ALDH1A1 404/4885HIF1A 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.